naltrexone and Weight Loss

naltrexone has been researched along with Weight Loss in 66 studies

Research

Studies (66)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	8 (12.12)	18.2507
2000's	8 (12.12)	29.6817
2010's	38 (57.58)	24.3611
2020's	12 (18.18)	2.80

Authors

Authors	Studies
Fineberg, SK; Grilo, CM; Gueorguieva, R; Ivezaj, V; Lydecker, JA; Moreno, JO	1
BouSaba, J; Camilleri, M; Dilmaghani, S; Prokop, LJ; Vosoughi, K	1
Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K	1
Lindblad, AJ; Luu, T; Paige, A; Thomas, B	2
Aloi, M; Arturi, F; Calabrò, G; Carbone, EA; Caroleo, M; Condoleo, F; de Filippis, R; Rania, M; Segura-Garcia, C; Staltari, FA	1
Capasso, A; De Biasio, V; Di Munzio, W; Foggia, G; Milano, W	1
Chung, WK; Febres, G; Holleran, S; Korner, J; LeDuc, CA; Mullally, JA; Ramakrishnan, R; Reid, TJ	1
Lee, SY; Tak, YJ	1
Abawi, O; van den Akker, ELT; van der Valk, ES; van der Voorn, B; van Rossum, EFC; Welling, MS	1
Aguilar-Salinas, C; Benchimol, A; Bonilha, I; Carvalho, LSF; Cercato, C; Geloneze, B; Hohl, A; Luchiari, B; Moura, F; Nadruz, W; Sposito, AC	1
Barakat, M; Blavignac, J; Burrows, M; Camacho, F; Christensen, RAG; Gould, E; Kamran, E; Wharton, S; Yin, P	1
Blundell, JE; Dalton, M; Duarte, C; Finlayson, G; Halseth, AE; Walsh, B	1
Wilding, JPH	1
Di Sessa, A; Grandone, A; Miraglia Del Giudice, E; Toraldo, R; Umano, GR	1
Barrea, L; Cataldi, M; Colao, A; Guida, B; Muscogiuri, G; Savastano, S; Taglialatela, M	1
Chatzis, P; Dinas, K; Makris, V; Pratilas, GC; Sotiriadis, A; Tziomalos, K	1
Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H	1
Billes, SK; Burns, C; Dunayevich, E; Fujioka, K; Greenway, FL; Gupta, AK; Kim, D; Smith, SR	1
Guloksuz, S; Reutenauer, EL; Srihari, VH; Tek, C	1
Caparelli, EC; Dunayevich, E; Telang, F; Tomasi, D; Volkow, ND; Wang, GJ; Wang, R	1
Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R	1
Billes, SK; Cowley, MA; Sinnayah, P	1
Bello, NT; Verpeut, JL	1
Hainer, V	1
Citrome, L	2
Fujioka, K	1
Chen, S; Gilder, K; Greenway, FL; Klassen, P; Kolotkin, RL	1
Apovian, CM	1
Megyeri, J; Nuffer, W; Trujillo, JM	1
Camilleri, M; Chandar, AK; Dulai, PS; Khera, R; Loomba, R; Murad, MH; Prokop, LJ; Singh, S; Wang, Z	1
Fujioka, K; Gilder, K; Greenway, FL; O'Neil, PM; Plodkowski, R; Walsh, B	1
Dybala, C; Foreyt, JP; Halseth, AE; Herrmann, K; Hong, K; Lam, H	1
Braverman-Panza, J; Fujioka, K	1
Brown, WA; Man Lee, CC; Oldfield, BJ; Stefanidis, A	1
Fujioka, K; Gilder, K; Halseth, A; Shan, K; Walsh, B	1
Curry, SA	1
Fitzpatrick, L; Harms, JF; Matters, GL; McGovern, C; Nilo, N; Parikh, A; Smith, JP	1
Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ	1
Chau, DL; Nguyen, L; Nguyen, Q; Plodkowski, RA; St Jeor, S; Sundaram, U	1
Fujioka, K; Lee, MW	1
Padwal, R	1
Cowley, MA; Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Tollefson, G	1
Kaplan, LM	1
Dunayevich, E; Erickson, JS; Foreyt, JP; Foster, GD; Hill, JO; Kim, DD; Klein, S; Maier, HN; O'Neil, PM; Perri, MG; Pi-Sunyer, FX; Rock, CL; Wadden, TA	1
Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA	1
Hatzitolios, AI; Katsiki, N; Mikhailidis, DP	1
Billes, SK; Greenway, FL	1
Gwinn, KM; Hurren, KM; Makowski, CT	1
Bello, NT; Liang, NC; Moran, TH	1
Goldfine, AB; Hiatt, WR; Thomas, A	1
Mercer, SL	1
Carter, R; Mouralidarane, A; Oben, J; Ray, S; Soeda, J	1
Bhardwaj, A; Chen, TY; Hurn, PD; Kirsch, JR; Koehler, RC; Toung, TJK; Traystman, RJ; Zhang, Z	1
Gamba, O; Gastaldi, M; Genazzani, AD; Genazzani, AR; Petraglia, F; Volpogni, C	1
Bailey, MD; Bhargava, HN; Bozek, PS; Gerk, PM; Ko, KH; Matwyshyn, GA; Simko, RJ; Thorat, SN	1
Adams, P; Anderson, LT; Campbell, M; Ernst, M; Gonzalez, NM; Small, AM	1
Carr, KD; Wolinsky, TD	1
Marín-Bivens, CL; Olster, DH	1
Boucher, M; Coudoré-Civiale, MA; Eschalier, A; Fournié-Zaluski, MC; Méen, M; Roques, BP	1
Kraft, K; Vetter, H	1
Fukagawa, Y; Misawa, M; Nagase, H; Suzuki, T	1
Aranow, JS; Kelsey, JE; Matthews, RT	1

Reviews

23 review(s) available for naltrexone and Weight Loss

Article	Year
Pharmacogenetic interactions of medications administered for weight loss in adults: a systematic review and meta-analysis. Pharmacogenomics, 2023, Volume: 24, Issue:5 Topics: Adult; Bupropion; Diabetes Mellitus, Type 2; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Naltrexone; Peptides; Pharmacogenetics; Protein Serine-Threonine Kinases; Venoms; Weight Loss	2023
Obesity: The New Global Epidemic Pharmacological Treatment, Opportunities and Limits for Personalized Therapy. Endocrine, metabolic & immune disorders drug targets, 2020, Volume: 20, Issue:8 Topics: Anti-Obesity Agents; Bupropion; Epidemics; Global Health; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Precision Medicine; Weight Loss	2020
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? Current obesity reports, 2021, Volume: 10, Issue:1 Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2021
Cardiovascular safety of naltrexone and bupropion therapy: Systematic review and meta-analyses. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2021, Volume: 22, Issue:6 Topics: Bupropion; Child; Female; Humans; Male; Naltrexone; Randomized Controlled Trials as Topic; Smoking Cessation; Tobacco Use Cessation Devices; Weight Loss	2021
New treatment modalities for obesity. Best practice & research. Clinical endocrinology & metabolism, 2018, Volume: 32, Issue:4 Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Benzazepines; Child; Diet; Humans; Naltrexone; Pediatric Obesity; Weight Loss	2018
Gender-related issues in the pharmacology of new anti-obesity drugs. Obesity reviews : an official journal of the International Association for the Study of Obesity, 2019, Volume: 20, Issue:3 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Dose-Response Relationship, Drug; Drug Combinations; Female; Humans; Liraglutide; Male; Naltrexone; Obesity; Patient Selection; Sex Factors; Topiramate; Treatment Outcome; Weight Loss	2019
The Role of Antiobesity Agents in the Management of Polycystic Ovary Syndrome. Folia medica, 2018, Dec-01, Volume: 60, Issue:4 Topics: Androgens; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Insulin Resistance; Liraglutide; Naltrexone; Obesity; Orlistat; Polycystic Ovary Syndrome; Weight Loss	2018
Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacological research, 2014, Volume: 84 Topics: Antidepressive Agents, Second-Generation; Bupropion; Drug Therapy, Combination; Energy Metabolism; Humans; Naltrexone; Narcotic Antagonists; Obesity; Weight Loss	2014
Drug safety evaluation of naltrexone/bupropion for the treatment of obesity. Expert opinion on drug safety, 2014, Volume: 13, Issue:6 Topics: Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Humans; Naltrexone; Obesity; Weight Loss	2014
Overview of new antiobesity drugs. Expert opinion on pharmacotherapy, 2014, Volume: 15, Issue:14 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Safety and tolerability of medications approved for chronic weight management. Obesity (Silver Spring, Md.), 2015, Volume: 23 Suppl 1 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Delayed-Action Preparations; Drug-Related Side Effects and Adverse Reactions; Drugs, Investigational; Fructose; Glucagon-Like Peptide 1; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; United States; United States Food and Drug Administration; Weight Loss	2015
Naltrexone/bupropion for the treatment of obesity and obesity with Type 2 diabetes. Future cardiology, 2016, Volume: 12, Issue:2 Topics: Adult; Anti-Obesity Agents; Bupropion; Diabetes Mellitus, Type 2; Drug Combinations; Humans; Naltrexone; Obesity; Weight Loss	2016
A Comparison of New Pharmacological Agents for the Treatment of Obesity. The Annals of pharmacotherapy, 2016, Volume: 50, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Clinical Trials, Phase III as Topic; Drug Combinations; Fructose; Humans; Liraglutide; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2016
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA, 2016, Jun-14, Volume: 315, Issue:22 Topics: Anti-Obesity Agents; Bayes Theorem; Benzazepines; Drug Combinations; Female; Fructose; Humans; Lactones; Liraglutide; Male; Middle Aged; Naltrexone; Obesity; Orlistat; Phentermine; Randomized Controlled Trials as Topic; Topiramate; Weight Loss	2016
Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:6 Topics: Animals; Bupropion; Chemistry, Pharmaceutical; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Weight Loss	2009
Naltrexone for the treatment of obesity: review and update. Expert opinion on pharmacotherapy, 2009, Volume: 10, Issue:11 Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Feeding Behavior; Humans; Naltrexone; Narcotic Antagonists; Obesity; Opioid Peptides; Weight Loss	2009
Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity. Current opinion in investigational drugs (London, England : 2000), 2009, Volume: 10, Issue:10 Topics: Administration, Oral; Animals; Appetite; Bupropion; Controlled Clinical Trials as Topic; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Drug Combinations; Energy Metabolism; Humans; Naltrexone; Narcotic Antagonists; Obesity; Weight Loss	2009
Pharmacologic therapies for obesity. Gastroenterology clinics of North America, 2010, Volume: 39, Issue:1 Topics: Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Cyclobutanes; Ephedrine; Fenfluramine; Humans; Lactones; Naltrexone; Obesity; Orlistat; Phentermine; Weight Gain; Weight Loss	2010
Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'? Annals of medicine, 2011, Volume: 43, Issue:4 Topics: Bupropion; Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Humans; Naltrexone; Obesity; Weight Loss	2011
Combination therapy with naltrexone and bupropion for obesity. Expert opinion on pharmacotherapy, 2011, Volume: 12, Issue:11 Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Weight Loss	2011
Naltrexone/bupropion: an investigational combination for weight loss and maintenance. Obesity facts, 2011, Volume: 4, Issue:6 Topics: Anti-Obesity Agents; Bupropion; Diabetes Mellitus; Drug Therapy, Combination; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Lipids; Naltrexone; Obesity; Quality of Life; Waist Circumference; Weight Loss	2011
ACS chemical neuroscience molecule spotlight on contrave. ACS chemical neuroscience, 2011, Sep-21, Volume: 2, Issue:9 Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Approval; Drug Combinations; Humans; Naltrexone; Obesity; Overweight; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Weight Loss	2011
Recent advancements in drug treatment of obesity. Clinical medicine (London, England), 2012, Volume: 12, Issue:5 Topics: Anti-Obesity Agents; Benzazepines; Benzoxazines; Bupropion; Clinical Trials as Topic; Drug Combinations; Fructose; Glucagon-Like Peptide 1; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Topiramate; Weight Loss	2012

Trials

15 trial(s) available for naltrexone and Weight Loss

Article	Year
Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial. The American journal of psychiatry, 2022, 12-01, Volume: 179, Issue:12 Topics: Behavior Therapy; Binge-Eating Disorder; Bupropion; Double-Blind Method; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Treatment Outcome; Weight Loss	2022
An open-label trial on the efficacy and tolerability of naltrexone/bupropion SR for treating altered eating behaviours and weight loss in binge eating disorder. Eating and weight disorders : EWD, 2021, Volume: 26, Issue:3 Topics: Binge-Eating Disorder; Bupropion; Case-Control Studies; Feeding Behavior; Humans; Naltrexone; Weight Loss	2021
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:5 Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Feeding Behavior; Female; Humans; Hypertension; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Overweight; Quality of Life; Risk Factors; Weight Loss	2013
Investigating the safety and efficacy of naltrexone for anti-psychotic induced weight gain in severe mental illness: study protocol of a double-blind, randomized, placebo-controlled trial. BMC psychiatry, 2013, Jun-27, Volume: 13 Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Clinical Protocols; Double-Blind Method; Female; Humans; Male; Mental Disorders; Middle Aged; Naltrexone; Narcotic Antagonists; Overweight; Psychotic Disorders; Research Design; Schizophrenia; Weight Gain; Weight Loss	2013
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes care, 2013, Volume: 36, Issue:12 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupropion; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Overweight; Retrospective Studies; Risk Factors; Treatment Outcome; Weight Loss; Young Adult	2013
Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. Clinical obesity, 2015, Volume: 5, Issue:5 Topics: Adult; Aged; Anti-Obesity Agents; Bupropion; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Quality of Life; Surveys and Questionnaires; Weight Loss; Young Adult	2015
The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy. International journal of obesity (2005), 2016, Volume: 40, Issue:9 Topics: Adolescent; Adult; Anti-Obesity Agents; Bupropion; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Naltrexone; Obesity; Risk Factors; Treatment Outcome; Weight Loss; Young Adult	2016
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes. Clinical obesity, 2016, Volume: 6, Issue:5 Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypertension; Incidence; Lost to Follow-Up; Male; Naltrexone; Nausea; Obesity; Overweight; Patient Dropouts; Severity of Illness Index; United States; Weight Loss	2016
Method-of-use study of naltrexone sustained release (SR)/bupropion SR on body weight in individuals with obesity. Obesity (Silver Spring, Md.), 2017, Volume: 25, Issue:2 Topics: Adolescent; Adult; Body Weight; Bupropion; Delayed-Action Preparations; Dopamine Uptake Inhibitors; Double-Blind Method; Exercise; Feeding Behavior; Female; Humans; Life Style; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Nausea; Obesity; Weight Loss; Young Adult	2017
Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring, Md.), 2009, Volume: 17, Issue:1 Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, Combination; Fasting; Female; Humans; Male; Mice; Mice, Obese; Naltrexone; Narcotic Antagonists; Obesity; Overweight; United States; Weight Loss	2009
Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. The Journal of clinical endocrinology and metabolism, 2009, Volume: 94, Issue:12 Topics: Adolescent; Adult; Appetite; Bupropion; Cohort Studies; Dopamine Uptake Inhibitors; Double-Blind Method; Drug Therapy, Combination; Endpoint Determination; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Positron-Emission Tomography; Risk Factors; Weight Loss; Young Adult	2009
Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring, Md.), 2011, Volume: 19, Issue:1 Topics: Adult; Antidepressive Agents; Behavior Therapy; Bupropion; Chemotherapy, Adjuvant; Combined Modality Therapy; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Placebos; Treatment Outcome; Weight Loss	2011
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England), 2010, Aug-21, Volume: 376, Issue:9741 Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Naltrexone; Obesity; Overweight; Weight Loss	2010
Naltrexone treatment restores menstrual cycles in patients with weight loss-related amenorrhea. Fertility and sterility, 1995, Volume: 64, Issue:5 Topics: Administration, Oral; Amenorrhea; Body Mass Index; Dose-Response Relationship, Drug; Estrogen Replacement Therapy; Estrogens; Female; Follicle Stimulating Hormone; Humans; Luteinizing Hormone; Menstrual Cycle; Naloxone; Naltrexone; Narcotic Antagonists; Progestins; Weight Loss	1995
Naltrexone in autistic children: behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry, 1993, Volume: 32, Issue:6 Topics: Attention; Autistic Disorder; Child; Child, Preschool; Discrimination Learning; Female; Humans; Male; Naltrexone; Psychiatric Status Rating Scales; Self-Injurious Behavior; Severity of Illness Index; Stereotyped Behavior; Treatment Outcome; Weight Loss	1993

Other Studies

28 other study(ies) available for naltrexone and Weight Loss

Article	Year
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long Diabetes, obesity & metabolism, 2023, Volume: 25, Issue:9 Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Humans; Liraglutide; Naltrexone; Obesity; Overweight; Peptides; Proglucagon; Weight Loss	2023
Naltrexone-bupropion for weight loss. Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:9 Topics: Bupropion; Humans; Naltrexone; Weight Loss	2023
Canadian family physician Medecin de famille canadien, 2023, Volume: 69, Issue:9 Topics: Bupropion; Humans; Naltrexone; Weight Loss	2023
Weight-loss response to naltrexone/bupropion is modulated by the Taq1A genetic variant near DRD2 (rs1800497): A pilot study. Diabetes, obesity & metabolism, 2021, Volume: 23, Issue:3 Topics: Bupropion; Genotype; Humans; Naltrexone; Pilot Projects; Polymorphism, Single Nucleotide; Protein Serine-Threonine Kinases; Receptors, Dopamine D2; Weight Loss	2021
[Pharmacotherapy for obesity]. Nederlands tijdschrift voor geneeskunde, 2021, 01-19, Volume: 165 Topics: Anti-Obesity Agents; Bariatric Surgery; Bupropion; Combined Modality Therapy; Drug Combinations; Drug Therapy, Combination; Humans; Hunger; Life Style; Liraglutide; Naltrexone; Obesity; Satiation; Treatment Outcome; Weight Loss	2021
Extended-release naltrexone/bupropion is safe and effective among subjects with type 2 diabetes already taking incretin agents: a post-hoc analysis of the LIGHT trial. International journal of obesity (2005), 2021, Volume: 45, Issue:8 Topics: Aged; Anti-Obesity Agents; Body Weight; Bupropion; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents; Incretins; Male; Middle Aged; Naltrexone; Obesity; Randomized Controlled Trials as Topic; Weight Loss	2021
Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample. International journal of obesity (2005), 2017, Volume: 41, Issue:8 Topics: Adult; Bupropion; Clinical Trials, Phase III as Topic; Craving; Dopamine Uptake Inhibitors; Feeding Behavior; Female; Food Preferences; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Obesity; Psychometrics; Surveys and Questionnaires; Treatment Outcome; Weight Loss	2017
Beyond lifestyle interventions: exploring the potential of anti-obesity medications in the UK. Clinical obesity, 2018, Volume: 8, Issue:3 Topics: Anti-Obesity Agents; Bariatric Surgery; Body Weight Maintenance; Bupropion; Health Services; Humans; Life Style; Liraglutide; Naltrexone; Obesity; Primary Health Care; Specialization; State Medicine; United Kingdom; Weight Loss; Weight Reduction Programs	2018
Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity. Diabetes, obesity & metabolism, 2013, Volume: 15, Issue:9 Topics: Absorptiometry, Photon; Adiposity; Analysis of Variance; Body Composition; Bupropion; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Humans; Intra-Abdominal Fat; Male; Middle Aged; Naltrexone; Obesity; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss	2013
Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues. International journal of obesity (2005), 2014, Volume: 38, Issue:5 Topics: Adolescent; Adult; Appetite; Bupropion; Cues; Diet; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Female; Ghrelin; Humans; Hypothalamus; Leptin; Magnetic Resonance Imaging; Meals; Naltrexone; Obesity; Peptide YY; Treatment Outcome; Weight Loss	2014
Contrave--a combination of bupropion and naltrexone for weight loss. The Medical letter on drugs and therapeutics, 2014, Nov-10, Volume: 56, Issue:1455 Topics: Anti-Obesity Agents; Bupropion; Drug Approval; Drug Combinations; Drug Interactions; Humans; Naltrexone; Obesity; Randomized Controlled Trials as Topic; United States; United States Food and Drug Administration; Weight Loss	2014
Lorcaserin, phentermine topiramate combination, and naltrexone bupropion combination for weight loss: the 15-min challenge to sort these agents out. International journal of clinical practice, 2014, Volume: 68, Issue:12 Topics: Benzazepines; Bupropion; Drug Combinations; Drug Prescriptions; Fructose; Humans; Naltrexone; Obesity; Phentermine; Topiramate; Weight Loss	2014
Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss. Prescrire international, 2015, Volume: 24, Issue:164 Topics: Anti-Obesity Agents; Blood Pressure; Bupropion; Drug Combinations; Drug Interactions; Humans; Mental Disorders; Naltrexone; Randomized Controlled Trials as Topic; Weight Loss	2015
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. The Journal of family practice, 2016, Volume: 65, Issue:7 Suppl Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones; Life Style; Liraglutide; Naltrexone; Obesity; Orlistat; Overweight; Phentermine; Primary Health Care; Risk Factors; Treatment Outcome; Weight Loss	2016
Improving efficacy of the adjustable gastric band: studies of the use of adjuvant approaches in a rodent model. Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery, 2017, Volume: 13, Issue:2 Topics: Adipose Tissue, Brown; Animals; Anti-Obesity Agents; Blood Glucose; Body Composition; Body Fat Distribution; Body Temperature; Bupropion; Diet, High-Fat; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Eating; Energy Metabolism; Gastroplasty; Glucose Intolerance; Injections, Subcutaneous; Insulin Resistance; Laparoscopy; Male; Naltrexone; Obesity; Physical Conditioning, Animal; Rats, Sprague-Dawley; Thermogenesis; Thyroxine; Weight Loss	2017
Obesity Epidemic: Pharmaceutical Weight Loss. Rhode Island medical journal (2013), 2017, Mar-01, Volume: 100, Issue:2 Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Drug Combinations; Fructose; Humans; Lactones; Liraglutide; Naltrexone; Obesity; Orlistat; Phentermine; Weight Loss	2017
The opioid antagonist naltrexone improves murine inflammatory bowel disease. Journal of immunotoxicology, 2008, Volume: 5, Issue:2 Topics: Animals; Biomarkers; Dextran Sulfate; Disease Models, Animal; Gene Expression Regulation; Humans; Inflammation Mediators; Inflammatory Bowel Diseases; Interleukin-12; Interleukin-6; Male; Mice; Naltrexone; Narcotic Antagonists; Weight Loss	2008
Miracle pills for weight loss: what is the number needed to treat, number needed to harm and likelihood to be helped or harmed for naltrexone-bupropion combination? International journal of clinical practice, 2010, Volume: 64, Issue:11 Topics: Adolescent; Adult; Aged; Anti-Obesity Agents; Body Mass Index; Bupropion; Delayed-Action Preparations; Drug Combinations; Drug Synergism; Female; Humans; Male; Middle Aged; Naltrexone; Numbers Needed To Treat; Obesity; Randomized Controlled Trials as Topic; Weight Loss; Young Adult	2010
Additive feeding inhibitory and aversive effects of naltrexone and exendin-4 combinations. International journal of obesity (2005), 2013, Volume: 37, Issue:2 Topics: Animals; Appetite Depressants; Body Weight; Drug Interactions; Drug Therapy, Combination; Eating; Exenatide; Hypoglycemic Agents; Male; Naltrexone; Obesity; Peptides; Rats; Rats, Sprague-Dawley; Taste; Venoms; Weight Loss	2013
What cost weight loss? Circulation, 2012, Mar-06, Volume: 125, Issue:9 Topics: Anti-Obesity Agents; Benzazepines; Bupropion; Cyclobutanes; Fructose; Humans; Naltrexone; Obesity; Phentermine; Risk Assessment; Risk Factors; Topiramate; Weight Loss	2012
Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats. Anesthesia and analgesia, 2003, Volume: 97, Issue:6 Topics: Animals; Behavior, Animal; Cerebral Cortex; Cranial Nerves; Functional Laterality; Gait; Hemodynamics; Ischemic Attack, Transient; Laser-Doppler Flowmetry; Male; Middle Cerebral Artery; Muscle Tonus; Naltrexone; Neuroprotective Agents; Pain; Piperidines; Putamen; Pyrrolidines; Rats; Rats, Wistar; Receptors, Opioid, kappa; Weight Loss	2003
Effects of naltrexone pellet implantation on morphine tolerance and physical dependence in the rat. General pharmacology, 1994, Volume: 25, Issue:1 Topics: Analgesia; Animals; Body Temperature; Dose-Response Relationship, Drug; Drug Implants; Drug Interactions; Drug Tolerance; Male; Morphine; Naltrexone; Rats; Rats, Sprague-Dawley; Substance Withdrawal Syndrome; Substance-Related Disorders; Time Factors; Weight Loss	1994
Chronic food restriction and weight loss produce opioid facilitation of perifornical hypothalamic self-stimulation. Brain research, 1993, Apr-02, Volume: 607, Issue:1-2 Topics: Animals; Behavior, Animal; Diet; Endorphins; Hypothalamic Area, Lateral; Injections, Intraventricular; Male; Naltrexone; Rats; Rats, Sprague-Dawley; Self Stimulation; Weight Loss	1993
Opioid receptor blockade promotes weight loss and improves the display of sexual behaviors in obese Zucker female rats. Pharmacology, biochemistry, and behavior, 1999, Volume: 63, Issue:3 Topics: Animals; Dose-Response Relationship, Drug; Eating; Estradiol; Female; Naltrexone; Narcotic Antagonists; Obesity; Ovariectomy; Progesterone; Rats; Rats, Zucker; Sexual Behavior, Animal; Steroids; Weight Loss	1999
Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats. British journal of pharmacology, 2001, Volume: 133, Issue:1 Topics: Aminopeptidases; Animals; Diabetes Mellitus, Experimental; Disulfides; Drug Synergism; Indoles; Male; Meglumine; Naloxone; Naltrexone; Neprilysin; Pain; Pain Measurement; Phenylalanine; Pressure; Rats; Rats, Sprague-Dawley; Receptor, Cholecystokinin B; Receptors, Cholecystokinin; Time Factors; Vocalization, Animal; Weight Loss	2001
Long-term opiate receptor antagonism in a patient with panhypopituitarism: effects on appetite, prolactin and demand for vasopressin. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1991, Volume: 23, Issue:2 Topics: Adult; Appetite; Drug Administration Schedule; Female; Humans; Hypopituitarism; Naltrexone; Obesity, Morbid; Prolactin; Vasopressins; Weight Loss	1991
Effects of chronic treatment with specific antagonists on analgesia and physical dependence on morphine in rats. Progress in clinical and biological research, 1990, Volume: 328 Topics: Analgesics; Animals; Indoles; Male; Morphinans; Morphine Dependence; Naloxone; Naltrexone; Narcotic Antagonists; Rats; Rats, Inbred Strains; Receptors, Opioid; Weight Loss	1990
Context-specific morphine withdrawal in rats: duration and effects of clonidine. Behavioral neuroscience, 1990, Volume: 104, Issue:5 Topics: Animals; Arousal; Association Learning; Clonidine; Male; Morphine; Morphine Dependence; Motor Activity; Naltrexone; Rats; Social Environment; Substance Withdrawal Syndrome; Weight Loss	1990